Precision BioSciences Raises $110M to Advance ARCUS Genome Editing ProgramsDURHAM, North Carolina, USA, June 26 2018 –Precision BioSciences today announced the closing of an oversubscribed $110M Series B financing to further product development efforts based on its ARCUS® genome editing platform. The financing was led by ArrowMark Partners and was joined by new investors Franklin Templeton Investments, Cowen Healthcare Investments, Brace Pharma Capital, Pontifax AgTech, OCV Partners, Adage Capital Management, Cormorant Asset Management, Gilead Sciences, Vivo Capital, Alexandria Venture Investments, Ridgeback Capital, Agent Capital, and entities affiliated with Leerink Partners. Existing investors venBio, F-Prime, RA Capital Management, Amgen Ventures, Osage University Partners, DUMAC, and the Longevity Fund also participated in the financing.
[button open_new_tab=”true” color=”accent-color” hover_text_color_override=”#fff” size=”medium” url=”https://elolife.ag/wp-content/uploads/2018/07/Precision_Bio_Series_B.pdf” text=”View Press Release” color_override=””]